Cingulate Inc (CING)

Cingulate Inc (CING) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $63.4M; returns 1 day +6.9%, 1 week +14.2%, 1 year +39.1%.

Cingulate Inc. (CING) is a clinical-stage biopharmaceutical company focused on developing treatments for attention deficit/hyperactivity disorder (ADHD) and anxiety, with a proprietary Precision Timed Release™ (PTR™) platform. Cingulate currently generates no revenue from product sales, relying on financing activities and grants to fund its drug development.

Groups CING belongs to

• Biopharmaceutical
• Clinical Stage Biopharma
• Clinical Stage
• Healthcare
• Biotechnology
• Pharmaceuticals
• CNS Disorders
• Neuroscience
• Precision Medicine
• Life Sciences

CING financial model: income statement, cash flow and balance sheet